Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short-term Investments: 2019-2025

Historic Short-term Investments for BridgeBio Pharma (BBIO) over the last 5 years, with Sep 2025 value amounting to $3.0 million.

  • BridgeBio Pharma's Short-term Investments fell 97.85% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 97.85%. This contributed to the annual value of $58.9 million for FY2023, which is 55.42% up from last year.
  • Per BridgeBio Pharma's latest filing, its Short-term Investments stood at $3.0 million for Q3 2025, which was down 62.33% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Short-term Investments peaked at $459.2 million during Q2 2021, and registered a low of $177,000 during Q4 2021.
  • For the 3-year period, BridgeBio Pharma's Short-term Investments averaged around $59.1 million, with its median value being $49.8 million (2023).
  • In the last 5 years, BridgeBio Pharma's Short-term Investments spiked by 21,329.38% in 2022 and then slumped by 97.85% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Short-term Investments (Quarterly) stood at $177,000 in 2021, then soared by 21,329.38% to $37.9 million in 2022, then soared by 55.42% to $58.9 million in 2023, then soared by 266.36% to $139.4 million in 2024, then crashed by 97.85% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $7.9 million for Q2 2025, and $139.4 million during Q3 2024.